Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

Elisabetta Fratta, Barbara Montico, Aurora Rizzo, Francesca Colizzi, Luca Sigalotti, Riccardo Dolcetti

Research output: Contribution to journalArticle


In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that "epigenetic drugs" are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination therapies are ongoing. The aim of this review is to provide a comprehensive summary of known epigenetic alterations and of the current use of epigenetic drugs for the treatment of hematological malignancies.

Original languageEnglish
Pages (from-to)57327-57350
Number of pages24
Issue number35
Publication statusPublished - 2016


  • 5-aza-2'-deoxycytidine
  • Azacytidine
  • DNA methylation
  • Hematological malignancies
  • Histone modifications

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies'. Together they form a unique fingerprint.

  • Cite this